CSF parameters associated with early MRI activity in patients with MS.
Adult
Biomarkers
/ cerebrospinal fluid
Cohort Studies
Demyelinating Diseases
/ cerebrospinal fluid
Disease Progression
Female
Humans
Immunoglobulin A
/ blood
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis
/ cerebrospinal fluid
Retrospective Studies
Risk Factors
Tumor Necrosis Factor Receptor Superfamily, Member 7
/ blood
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
28
06
2018
accepted:
21
03
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
2
10
2020
Statut:
epublish
Résumé
To identify CSF parameters at diagnosis of clinically isolated syndrome (CIS) and MS that are associated with early inflammatory disease activity as measured by standardized cerebral MRI (cMRI). One hundred forty-nine patients with newly diagnosed CIS and MS were included in the retrospective study. cMRI at onset and after 12 months was analyzed for T2 and gadolinium-enhancing lesions. CSF was tested for oligoclonal bands and intrathecal synthesis of immunoglobulin G (IgG), A (IgA), and M (IgM) before initiation of disease-modifying therapy (DMT). In a subgroup of patients, CSF and serum samples were analyzed for sCD27, neurofilament light chain, and IgG subclasses 1 and 3. Association between CSF parameters and cMRI activity was investigated by univariable and multivariable regression analysis in all patients, DMT-treated patients, and untreated patients. IgG index, sCD27 levels in CSF, and to a lesser extent IgM index were associated with the occurrence of new cMRI lesions. IgG index and sCD27 levels in CSF were highly correlated. In a multivariable analysis, IgG index and to a lesser extent IgM index together with DMT treatment status and gender were strongest predictors of future cMRI activity. CSF parameters such as IgG and IgM index are independently associated with future MRI activity and thus might be helpful to support early treatment decisions in patients newly diagnosed with CIS and MS.
Identifiants
pubmed: 31355309
doi: 10.1212/NXI.0000000000000573
pii: NEURIMMINFL2018017624
pmc: PMC6624100
doi:
Substances chimiques
Biomarkers
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Tumor Necrosis Factor Receptor Superfamily, Member 7
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e573Références
Lancet. 2001 May 19;357(9268):1576-82
pubmed: 11377645
J Neuroimmunol. 2001 Dec 3;121(1-2):120-5
pubmed: 11730948
Neurology. 2004 Nov 9;63(9):1586-90
pubmed: 15534240
J Neuroimmunol. 1991 Dec;35(1-3):211-7
pubmed: 1659587
Neurology. 2007 Apr 24;68(17):1390-401
pubmed: 17452584
Neurology. 2008 Mar 25;70(13 Pt 2):1079-83
pubmed: 17881717
Mult Scler. 2008 Mar;14(2):183-7
pubmed: 17942517
Brain. 2008 Mar;131(Pt 3):808-17
pubmed: 18234696
J Neurol Sci. 2010 Jan 15;288(1-2):147-50
pubmed: 19828154
Mult Scler. 2012 May;18(5):587-91
pubmed: 21965422
Neuroimage. 2012 Feb 15;59(4):3774-83
pubmed: 22119648
Arch Neurol. 2012 Oct;69(10):1259-69
pubmed: 22751847
Mult Scler. 2013 Jul;19(8):1074-83
pubmed: 23234810
J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):909-14
pubmed: 23431079
J Neuroimmunol. 2013 Apr 15;257(1-2):76-81
pubmed: 23434160
Mult Scler. 2013 Sep;19(10):1310-9
pubmed: 23447359
Mult Scler. 2015 Jul;21(8):1013-24
pubmed: 25680984
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9
pubmed: 25716934
Brain. 2015 Jul;138(Pt 7):1863-74
pubmed: 25902415
Mult Scler. 2016 May;22(6):770-81
pubmed: 26362893
Mult Scler. 2016 Oct;22(12):1550-1559
pubmed: 26754800
Eur J Neurol. 2016 May;23(5):898-905
pubmed: 26872061
Neurol Neuroimmunol Neuroinflamm. 2016 Apr 20;3(3):e219
pubmed: 27144214
Neurology. 2016 Sep 13;87(11):1076-84
pubmed: 27521440
JAMA Neurol. 2017 Mar 1;74(3):286-292
pubmed: 28055081
Neurology. 2017 Feb 28;88(9):826-831
pubmed: 28148632
Eur J Neurol. 2017 May;24(5):703-712
pubmed: 28261960
Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422
pubmed: 29209636
Neurol Neuroimmunol Neuroinflamm. 2018 Jan 22;5(2):e435
pubmed: 29435472
Mult Scler. 2019 Apr;25(5):678-686
pubmed: 29542376
Ann Neurol. 2018 May;83(5):1032-1036
pubmed: 29665046
Mult Scler. 2018 Nov;24(13):1715-1724
pubmed: 30019626
Front Immunol. 2018 Jul 13;9:1590
pubmed: 30057580
Mult Scler. 2018 Aug 16;:1352458518794308
pubmed: 30113249
Clin Chim Acta. 1987 Mar 30;163(3):319-28
pubmed: 3581475